FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and medicine. What is described is an active immunostimulating vaccine containing at least one RNA, preferentially iRNA coding at least two antigens evoking the immune response in a mammal and used for treating lung cancer, first non-small cells lung cancer (NSCLC), preferentially specified among three primary subtypes, squamous cell carcinoma, adenocarcinoma and large-cell lung carcinoma, or NSCLS-related disorders.
EFFECT: there are produced kits, first containing the active immunostimulating vaccine.
21 cl, 34 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| NUCLEIC ACID COMPRISING OR CODING HISTONE STEM-LOOP AND POLY(A)-SEQUENCE OR POLYADENYLATION SIGNAL FOR INCREASING EXPRESSION OF ENCODED TUMOUR ANTIGEN | 2013 |
|
RU2650795C2 |
| NUCLEIC ACID CONTAINING OR CODING HISTONE STRUCTURE OF STEM-LOOP TYPE AND POLY(A)-SEQUENCE OR POLYADENYLATION SIGNAL FOR INCREASING EXPRESSION OF ENCODED TUMOUR ANTIGEN | 2013 |
|
RU2718577C2 |
| COMPOSITION CONTAINING COMPLEX (M)RNA AND FREE MRNA FOR IMPLEMENTING OR IMPROVING IMMUNOSTIMULATORY RESPONSE IN MAMMALS AND USING IT | 2009 |
|
RU2545756C2 |
| POLYEPITOPE IMMUNOGENIC POLYPEPTIDES AND METHODS OF APPLICATION THEREOF | 2013 |
|
RU2598265C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND PROMOTER | 2015 |
|
RU2799573C2 |
| COMBINATION OF ANTI-CANCER RNA VACCINE AND PD-1 PATHWAY INHIBITOR AND ITS APPLICATION | 2014 |
|
RU2718988C2 |
| COMPLEXES BASED ON RNA AND CATION PEPTIDES FOR TRANSFECTION AND IMMUNOPOTENTIATION | 2008 |
|
RU2493256C2 |
| CANCER THERAPY COMBINING LYMPHOEXHAUSTING AGENT WITH CYTOTOXIC LYMPHOCYTES AND CYTOKINES | 2007 |
|
RU2447900C2 |
